Rat studies covered the long post-injury period (one year), and, in particular, the immediate period following application, given at the time of the early or late course of the spinal compression
Human clinical-trial data (Phase 1/2 studies in wound healing, cardiac injury, and dry eye) exist only for a different, full-length recombinant thymosin beta-4 product, not for the short synthetic fragment marketed as TB-500, so no completed published human trial has evaluated TB-500 specifically for muscle, tendon, or joint recovery
Park et al., 2020), its relationship to the nitric oxide (NO)-system (Sikiric et al., 2014), and blood vessels (Sikiric et al., 2006
The interaction between BPC-157 and early EGR-1 appears to involve specific molecular mechanisms
Research suggests BPC-157 may upregulate VEGF signaling involved in angiogenesis and tissue repair, and modulate nitric oxide pathways linked to tissue perfusion
Its a marketing term, not a scientific one